Physician profile
Jeffry Tambor
NPI 1679677892
$3,799.72
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $640 · 2021: $731 · 2022: $1,176 · 2023: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $596.98 | 2019-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $530.45 | 2020-2023 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $353.90 | 2020-2023 | Trintellix |
| Glaxosmithkline, LLC. | $348.75 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $251.39 | 2020-2023 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $185.69 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $180.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.24 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.45 | 2019-2021 | |
| Corium, LLC | $94.23 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $84.95 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $79.99 | 2022-2023 | |
| Allergan, INC. | $72.68 | 2020 | |
| Janssen Pharmaceuticals, INC | $61.20 | 2019-2021 | |
| Genentech USA, INC. | $59.22 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $57.74 | 2019-2022 | |
| Pfizer INC. | $51.48 | 2020-2022 | |
| Orexo US, INC. | $45.94 | 2022 | |
| Amarin Pharma, INC. | $44.54 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.67 | 2022-2023 | Xifaxan |
| Eisai INC. | $40.22 | 2020 | |
| Indivior INC. | $35.17 | 2021 | |
| Insulet Corporation | $34.12 | 2023 | Omnipod |
| Lundbeck LLC | $30.76 | 2023 | Rexulti |
| Cumberland Pharmaceuticals, INC. | $29.94 | 2023 | Kristalose |
| Amgen INC. | $29.70 | 2021 | |
| Almatica Pharma LLC | $29.04 | 2022 | |
| Antares Pharma, INC. | $24.87 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.14 | 2021 | |
| Abbott Laboratories | $20.17 | 2022 | |
| Astellas Pharma US INC | $20.00 | 2020 | |
| Aytu Biopharma, INC. | $19.78 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.92 | 2022 | |
| Exact Sciences Corporation | $17.48 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.65 | 2023 | Livalo, Seglentis |
| Bausch Health US, LLC | $14.39 | 2021 | |
| Merck Sharp & Dohme LLC | $12.47 | 2020 | |
| Horizon Therapeutics Plc | $11.66 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffry Tambor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.